Table 1.
Univariate and multivariate analyses of the comparison of clinical, pathological, and molecular characteristics of WDTC samples in relation to the risk of relapse.
| Variable | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| HR (CI95%) | p | HR (CI95%) | p | |
| Age | ||||
| <55 years | 1.0 | |||
| ≥55 years | 0.48 (0.11–2.05) | 0.325 | ||
| Gender | ||||
| Female | 1.0 | 1.0 | ||
| Male | 3.63 (1.65–7.98) | 0.001 | 1.89 (0.65–5.47) | 0.242 |
| Tumor Size (cm) | ||||
| ≤1 cm | 1.0 | |||
| >1 cm | 1.69 (0.71–4.05) | 0.239 | ||
| Multicentricity | ||||
| No | 1.0 | 1.0 | ||
| Yes | 2.10 (0.95–4.63) | 0.066 | 1.53 (0.58–4.05) | 0.396 |
| Histology | ||||
| PTC | 1.0 | |||
| FTC | 1.08 (0.25–4.57) | 0.919 | ||
| PTC Variant | ||||
| Classic | 1.0 | |||
| Others | 0.43 (0.13–1.43) | 0.169 | ||
| Extrathyroidal Extension | ||||
| No | 1.0 | 1.0 | ||
| Yes | 1.96 (0.89–4.31) | 0.093 | 1.53 (0.41–5.61) | 0.525 |
| Lymph node Metastasis | ||||
| No (cN0, pN0) | 1.0 | 1.0 | ||
| Yes (pN1) | 4.19 (1.85–9.51) | <0.001 | 5.77 (0.64–52) | 0.118 |
| Risk stratification * | ||||
| Low | 1.0 | 1.0 | ||
| Intermediate | 2.49 (0.98–6.33) | 0.055 | 0.35 (0.03–4.54) | 0.419 |
| High | 6.08 (1.22–30.35) | 0.028 | 0.35 (0.01–12.36) | 0.563 |
| BRAFV600E # | ||||
| No | 1.0 | 1.0 | ||
| Yes | 0.98 (0.42–2.26) | 0.955 | 0.74 (0.27–2.02) | 0.560 |
| TERT C228T/C250T | ||||
| No | 1.0 | |||
| Yes | 1.21 (0.16–8.95) | 0.854 | ||
| CXXC5 Methylation | ||||
| Below Median | 1.22 (0.51–2.94) | 0.658 | ||
| Above Median | 1.0 | |||
| ATP6V0C Methylation | ||||
| Below Median | 1.0 | |||
| Above Median | 1.93 (0.85–4.36) | 0.116 | ||
| PFKFB2 Methylation | ||||
| Below Median | 3.85 (1.42–10.44) | 0.008 | 3.17 (1.06–9.46) | 0.038 |
| Above Median | 1.0 | 1.0 | ||
HR: hazard ratio; p: obtained from Cox regression model. CI95%: 95% confidence interval; PTC: papillary thyroid carcinoma; FTC: follicular thyroid carcinoma; cN0: no clinical evidence of lymph nodes involvement; pN0: no pathologically evidence of lymph nodes involvement; pN1: pathological confirmation of lymph nodes involvement; * American Thyroid Association recurrence risk stratification [4]; # variable entered in the multivariate model, since an association with PFKFB2 methylation was detected; bold: significant p-value.